"Drug Synergism" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The action of a drug in promoting or enhancing the effectiveness of another drug.
| Descriptor ID |
D004357
|
| MeSH Number(s) |
G07.690.773.968.477
|
| Concept/Terms |
Drug Synergism- Drug Synergism
- Drug Synergisms
- Synergism, Drug
- Synergisms, Drug
Drug Potentiation- Drug Potentiation
- Drug Potentiations
- Potentiation, Drug
- Potentiations, Drug
Drug Augmentation- Drug Augmentation
- Augmentation, Drug
- Augmentations, Drug
- Drug Augmentations
|
Below are MeSH descriptors whose meaning is more general than "Drug Synergism".
Below are MeSH descriptors whose meaning is more specific than "Drug Synergism".
This graph shows the total number of publications written about "Drug Synergism" by people in this website by year, and whether "Drug Synergism" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 2 | 2 |
| 1996 | 0 | 2 | 2 |
| 1997 | 0 | 5 | 5 |
| 1998 | 0 | 7 | 7 |
| 1999 | 0 | 3 | 3 |
| 2000 | 0 | 5 | 5 |
| 2001 | 0 | 7 | 7 |
| 2002 | 0 | 11 | 11 |
| 2003 | 0 | 6 | 6 |
| 2004 | 0 | 7 | 7 |
| 2005 | 1 | 6 | 7 |
| 2006 | 0 | 7 | 7 |
| 2007 | 0 | 4 | 4 |
| 2008 | 0 | 5 | 5 |
| 2009 | 0 | 14 | 14 |
| 2010 | 0 | 5 | 5 |
| 2011 | 0 | 7 | 7 |
| 2012 | 1 | 7 | 8 |
| 2013 | 0 | 8 | 8 |
| 2014 | 0 | 6 | 6 |
| 2015 | 0 | 12 | 12 |
| 2016 | 0 | 8 | 8 |
| 2017 | 1 | 7 | 8 |
| 2018 | 0 | 7 | 7 |
| 2019 | 0 | 3 | 3 |
| 2020 | 0 | 8 | 8 |
| 2021 | 0 | 2 | 2 |
| 2022 | 0 | 1 | 1 |
| 2024 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Synergism" by people in Profiles.
-
A kinome drug screen identifies multi-TKI synergies and ERBB2 signaling as a therapeutic vulnerability in MYC/TYR subgroup atypical teratoid rhabdoid tumors. Neuro Oncol. 2024 Oct 03; 26(10):1895-1911.
-
A drug repurposing screen identifies decitabine as an HSV-1 antiviral. Microbiol Spectr. 2024 Nov 05; 12(11):e0175424.
-
A host-directed oxadiazole compound potentiates antituberculosis treatment via zinc poisoning in human macrophages and in a mouse model of infection. PLoS Biol. 2024 Apr; 22(4):e3002259.
-
XP-524 is a dual-BET/EP300 inhibitor that represses oncogenic KRAS and potentiates immune checkpoint inhibition in pancreatic cancer. Proc Natl Acad Sci U S A. 2022 01 25; 119(4).
-
The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma. Nat Commun. 2021 11 09; 12(1):6468.
-
Treatment with a neutrophil elastase inhibitor and ofloxacin reduces P. aeruginosa burden in a mouse model of chronic suppurative otitis media. NPJ Biofilms Microbiomes. 2021 04 06; 7(1):31.
-
OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia. Blood Cancer J. 2021 03 03; 11(3):48.
-
Attenuation of SRC Kinase Activity Augments PARP Inhibitor-mediated Synthetic Lethality in BRCA2-altered Prostate Tumors. Clin Cancer Res. 2021 03 15; 27(6):1792-1806.
-
Inhibition of DNA-PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC. Int J Oncol. 2020 10; 57(4):939-955.
-
Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy. J Hematol Oncol. 2020 06 09; 13(1):74.